DF-003 for ROSAH Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Do I need to stop my current medications for the trial?
Yes, you may need to stop certain medications. The trial prohibits the use of specific drugs, including some anti-inflammatory agents, certain antibiotics, and medications affecting liver enzymes. Check with the trial team to see if your current medications are on the prohibited list.
Who Is on the Research Team?
Kathleen Digre
Principal Investigator
University of Utah (Moran Eye Center)
Oleg Alekseev
Principal Investigator
Duke University (Duke Eye Center)
John Grigg
Principal Investigator
University of Sydney (Save Sight Institute)
Simon Chatfield
Principal Investigator
Melbourne Health
Are You a Good Fit for This Trial?
This trial is for individuals with ROSAH syndrome, a condition that affects the skin. Participants must meet certain health criteria to join, but specific inclusion and exclusion details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral doses of DF-003 once daily for 28 days, with loading doses on Days 1-3 followed by maintenance doses from Day 4 to Day 28
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DF-003
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Lead Sponsor